Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe

Executive Summary

Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.

Advertisement

Related Content

Dr Reddy’s Management Upbeat Despite Product Delays
Product Delays Dull Dr Reddy’s Despite Upbeat Management
M&A A Major Pillar Of Sumitomo Dainippon's New Mid-Term Plan
Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration
Dr Reddy’s CEO On Payer Dynamics, China Commitment And Disruption
Cipla Backs Start-Up As It Builds Digital Health Strategy
Record Dr Reddy's US Launches In Q3 Set Tone For Earnings Pick Up?
EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
Keeping Track: US FDA Clears Three Novel Agents Over Three Days – Bavencio, Symproic And Xadago
Dr Reddy's Pumps Complex Generics Play with Teva deal

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC125091

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel